The Food and Drug Administration of USA (FDA) has approved a new treatment that provides relief 24 hours a day of the symptoms caused by its disease Parkinson.
Onapgo therapy is essentially a subcutaneous device of continuous injection of the dopamine hydrochloride hydrochloride, which helps manage the symptoms of Parkinson’s disease and is expected to be available in the US by the end of 2025.
Clinical trials showed that the device significantly reduced daily episodes on average 2.47 hours, compared to virtual treatment (0.58 hours).
“This treatment is able to change the data by helping us to provide more personalized and effective care to people living with Parkinson’s disease. In addition, as more treatments are approved, the need for continuing innovation in the development of drugs and especially those who focus on the control of symptoms is reinforced, without having to rely on oral medicines, “Kelly Papas, executive, executive, Neurobiologylive.
“As Parkinson’s disease progresses, levodopa therapy often becomes less effective in providing consistent motor control, partly due to gastrointestinal dyskinesia, variable absorption of oral drugs and subsequent pulsating stimulation of dopamine trails.” Stewart Esakson, director of the Parkinson’s Center and Boca Raton’s motor disorders in Florida, who was also one of the clinical trials clinical trial.
“The constant injection of apionmmmine offers onapgo immediately stimulates the post -consistent dopamine receptors without the need for metabolic conversion. In addition, subcutaneous administration of aposthemine bypasses the gastrointestinal system and enters the brain, which can allow more predictable improvement of symptoms, ”he added.
The new approved injection device offers better management of symptoms without the need for surgery. The approval of treatment will also be accompanied by a training program for health professionals.